MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/joa3.12840

Медицинская библиотека · Journal of arrhythmia · 2023

Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS-SPAF).

Jung Moonki, Byeon Kyeongmin, Kang Ki-Woon, Lee Wang-Soo, Kim Sang Wook, Park Yae Min, Hwang You Mi, Lee Sung Ho, Jin Eun-Sun, Roh Seung-Young, Kim Jin Seok, Ahn Jinhee, Lee So-Ryoung, Choi Eue-Keun, Ahn Min-Soo, Lee Eun Mi, Park Hwan-Cheol, Lee Ki Hong, Kim Min, Choi Joon Hyouk, Ko Jum Suk, Kim Jin Bae, Kim Changsoo, Lip Gregory Y H, Shin Seung Yong, Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS‐SPAF) Investigators

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The balance of stroke risk reduction and potential bleeding risk associated with antithrombotic treatment (ATT) remains unclear in atrial fibrillation (AF) at non-gender CHA2DS2-VASc scores 0-1. A net clinical benefit (NCB) analysis of ATT may guide stroke prevention strategies in AF with non-gender CHA2DS2-VASc scores 0-1.

METHODS

This multi-center cohort study evaluated the clinical outcomes of treatment with a single antiplatelet (SAPT), vitamin K antagonist (VKA), and non-VKA oral anticoagulant (NOAC) in non-gender CHA2DS2-VASc score 0-1 and further stratified by biomarker-based ABCD score (Age [≥60 years], B-type natriuretic peptide [BNP] or N-terminal pro-BNP [≥300 pg/mL], creatinine clearance [<50 mL/min], and dimension of the left atrium [≥45 mm]). The primary outcome was the NCB of ATT, including composite thrombotic events (ischemic stroke, systemic embolism, and myocardial infarction) and major bleeding events.

RESULTS

We included 2465 patients (age 56.2 ± 9.5 years; female 27.0%) followed-up for 4.0 ± 2.8 years, of whom 661 (26.8%) were treated with SAPT; 423 (17.2%) with VKA; and 1040 (42.2%) with NOAC. With detailed risk stratification using the ABCD score, NOAC showed a significant positive NCB compared with the other ATTs (SAPT vs. NOAC, NCB 2.01, 95% confidence interval [CI] 0.37-4.66; VKA vs. NOAC, NCB 2.38, 95% CI 0.56-5.40) in ABCD score ≥1. ATT failed to show a positive NCB in patients with truly low stroke risk (ABCD score = 0).

CONCLUSIONS

In the Korean AF cohort at non-gender CHA2DS2-VASc scores 0-1, NOAC showed significant NCB advantages over VKA or SAPT with ABCD score ≥1.

Для цитирования: Jung Moonki, Byeon Kyeongmin, Kang Ki-Woon, Lee Wang-Soo, Kim Sang Wook, Park Yae Min, Hwang You Mi, Lee Sung Ho, Jin Eun-Sun, Roh Seung-Young, Kim Jin Seok, Ahn Jinhee, Lee So-Ryoung, Choi Eue-Keun, Ahn Min-Soo, Lee Eun Mi, Park Hwan-Cheol, Lee Ki Hong, Kim Min, Choi Joon Hyouk, Ko Jum Suk, Kim Jin Bae, Kim Changsoo, Lip Gregory Y H, Shin Seung Yong, Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS‐SPAF) Investigators. Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS-SPAF).. Journal of arrhythmia. 2023. DOI: 10.1002/joa3.12840.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.